WASHINGTON (dpa-AFX) - Edwards Lifesciences (EW) said it has exercised its
option to acquire Innovalve Bio Medical, an early-stage transcatheter mitral
valve replacement company, following its initial investment in 2017. Innovalve
will join the transcatheter mitral and tricuspid therapies product group, led by
corporate vice president, Daveen Chopra.

'Edwards' SAPIEN M3 remains on track to become the first approved transfemoral
TMVR system in Europe by the end of 2025. We believe the Innovalve technologies,
paired with Edwards' deep mitral expertise, will enable a TMVR platform that
will expand the treatable population,' said Daveen Chopra.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX